Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.12
FLML's Cash to Debt is ranked higher than
56% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.05 vs. FLML: 1.12 )
FLML' s 10-Year Cash to Debt Range
Min: 0.08   Max: No Debt
Current: 1.12

Equity to Asset 0.43
FLML's Equity to Asset is ranked higher than
53% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. FLML: 0.43 )
FLML' s 10-Year Equity to Asset Range
Min: -0.32   Max: 0.8
Current: 0.43

-0.32
0.8
F-Score: 5
Z-Score: 0.57
M-Score: -3.99
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -222.94
FLML's Operating margin (%) is ranked higher than
53% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.76 vs. FLML: -222.94 )
FLML' s 10-Year Operating margin (%) Range
Min: -222.94   Max: 15.94
Current: -222.94

-222.94
15.94
Net-margin (%) -191.26
FLML's Net-margin (%) is ranked higher than
54% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. FLML: -191.26 )
FLML' s 10-Year Net-margin (%) Range
Min: -191.26   Max: 22.56
Current: -191.26

-191.26
22.56
ROA (%) -36.92
FLML's ROA (%) is ranked higher than
53% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.69 vs. FLML: -36.92 )
FLML' s 10-Year ROA (%) Range
Min: -46.47   Max: 13.02
Current: -36.92

-46.47
13.02
ROC (Joel Greenblatt) (%) -220.37
FLML's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.52 vs. FLML: -220.37 )
FLML' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -551.23   Max: 48.65
Current: -220.37

-551.23
48.65
Revenue Growth (%) -16.70
FLML's Revenue Growth (%) is ranked higher than
58% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. FLML: -16.70 )
FLML' s 10-Year Revenue Growth (%) Range
Min: -16.7   Max: 42.6
Current: -16.7

-16.7
42.6
EBITDA Growth (%) 120.40
FLML's EBITDA Growth (%) is ranked higher than
98% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. FLML: 120.40 )
FLML' s 10-Year EBITDA Growth (%) Range
Min: -50.2   Max: 120.4
Current: 120.4

-50.2
120.4
EPS Growth (%) 65.90
FLML's EPS Growth (%) is ranked higher than
97% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. FLML: 65.90 )
FLML' s 10-Year EPS Growth (%) Range
Min: -38.2   Max: 88.8
Current: 65.9

-38.2
88.8
» FLML's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

FLML Guru Trades in

FLML Guru Trades in

Q2 2012

FLML Guru Trades in Q2 2012

Jim Simons 89,300 sh (+1.02%)
» More
Q3 2012

FLML Guru Trades in Q3 2012

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with FLML

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2012-03-31 Sold Out 0.0048%$5.08 - $7.67 $ 15.19163%0
Jean-Marie Eveillard 2011-06-30 Add 21.28%$5.02 - $6.629 $ 15.19159%209200
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.45
FLML's P/B is ranked lower than
60% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.38 vs. FLML: 7.45 )
FLML' s 10-Year P/B Range
Min: 1.83   Max: 44.64
Current: 7.45

1.83
44.64
P/S 15.41
FLML's P/S is ranked lower than
65% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.42 vs. FLML: 15.41 )
FLML' s 10-Year P/S Range
Min: 2.3   Max: 44.18
Current: 15.41

2.3
44.18
EV-to-EBIT -6.16
FLML's EV-to-EBIT is ranked lower than
56% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. FLML: -6.16 )
FLML' s 10-Year EV-to-EBIT Range
Min: 27.3   Max: 125.4
Current: -6.16

27.3
125.4
Current Ratio 2.92
FLML's Current Ratio is ranked higher than
70% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. FLML: 2.92 )
FLML' s 10-Year Current Ratio Range
Min: 0.57   Max: 6.76
Current: 2.92

0.57
6.76
Quick Ratio 2.78
FLML's Quick Ratio is ranked higher than
74% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. FLML: 2.78 )
FLML' s 10-Year Quick Ratio Range
Min: 0.52   Max: 6.7
Current: 2.78

0.52
6.7

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 25.74
FLML's Price/Tangible Book is ranked lower than
62% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.90 vs. FLML: 25.74 )
FLML' s 10-Year Price/Tangible Book Range
Min: 1.39   Max: 35.11
Current: 25.74

1.39
35.11
Price/Median PS Value 2.48
FLML's Price/Median PS Value is ranked lower than
56% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.20 vs. FLML: 2.48 )
FLML' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 5.55
Current: 2.48

0.24
5.55
Earnings Yield (Greenblatt) 1.40
FLML's Earnings Yield (Greenblatt) is ranked lower than
60% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.90 vs. FLML: 1.40 )
FLML' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 3.7
Current: 1.4

0.8
3.7
Forward Rate of Return (Yacktman) -5.16
FLML's Forward Rate of Return (Yacktman) is ranked higher than
98% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.94 vs. FLML: -5.16 )
FLML' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.1   Max: 0.2
Current: -5.16

0.1
0.2

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:FL3.Germany
Flamel Technologies, S.A. is organized as a societe anonyme, a form of corporation under the laws of The Republic of France. The Company was founded in 1990. It is a biopharmaceutical company principally engaged in the development of two unique polymer-based drug delivery technologies. The Company's nanoparticle Medusa technology is designed to provide controlled release following injection of therapeutic proteins, peptides and other large and small molecules. It also has developed a microparticule adaptation of the Medusa platform which it offers important advantages in the delivery of smaller proteins and peptides. The Company's Micropump technology is a multiparticle technology for oral administration of small molecule drugs with applications in controlled-release, taste-masking and bioavailability enhancement. The Company's Trigger-Lock technology is an adaptation of Micropump designed to minimize the misuse and abuse of medications subject to abuse. The Company operates mainly in France. It competes with academic laboratories, research institutions, universities, joint ventures, and other pharmaceutical and biotechnology companies, including other companies developing drug delivery systems. Some of these competitors are also its business partners. In the United States, the FDA regulates such products under various federal statutes, including the Federal Food, Drug, and Cosmetic Act (FDCA) and the Public Health Service Act. Similar requirements exist in the Member States of the European Union.
» More Articles for NAS:FLML

Headlines

Articles On GuruFocus.com
Flamel Technologies Announces Second Quarter 2009 Results; Multiple New Projects; Cash Increases fro Aug 05 2009 
Flamel Technologies Announces Projected Release Date of Second Quarter Results; Conference Call Jul 28 2009 


More From Other Websites
Nasdaq stocks posting largest percentage increases Aug 22 2014
Flamel Technologies SA (FLML) in Focus: Stock Rises 8% Aug 22 2014
Flamel Technologies SA (FLML) Soars: Stock Rises 10.9% Aug 05 2014
Flamel Notified of FDA Communication to Unapproved Manufacturers of Neostigmine Methylsulfate Aug 04 2014
Flamel Notified of FDA Communication to Unapproved Manufacturers of Neostigmine Methylsulfate Aug 04 2014
Flamel Technologies Announces Second Quarter of Fiscal Year 2014 Results Jul 29 2014
Q2 2014 Flamel Technologies Earnings Release - Before Market Open Jul 29 2014
Flamel Technologies Announces Second Quarter of Fiscal Year 2014 Results Jul 29 2014
Flamel Technologies to Report Second Quarter of Fiscal Year 2014 Results Jul 28 2014
Flamel Technologies to Report Second Quarter of Fiscal Year 2014 Results Jul 22 2014
Weakness Seen in Lannett Company (LCI): Stock Tumbles 17.1% Jul 17 2014
Flamel Technologies has multiple catalysts in second half, says Summer Street Jul 16 2014
Flamel Technologies: Bloxiverz Competition To Cease Marketing Jul 09 2014
Flamel Technologies Announces Results of 2014 Annual Meeting Jul 03 2014
Flamel Technologies Announces Results of 2014 Annual Meeting Jul 02 2014
Flamel Technologies Announces FDA Approval of VAZCULEP Jun 30 2014
Flamel Technologies announces exenatide preclinical results Jun 25 2014
Flamel Technologies Announces Positive Preclinical Results For Its Once-a-Week Formulation of... Jun 25 2014
Flamel Technologies (FLML) Jumps: Stock Adds 18.8% in Session Jun 23 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide